Melus (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, reducing the production of prostaglandins that drive inflammation, pain, and fever. By lowering prostaglandin levels at inflamed sites, it diminishes the inflammatory response while sparing COX‑1 activity that protects the stomach lining.

The appropriate dose of Melus is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Meloxicam is generally not recommended during pregnancy, especially in the third trimester, because of potential risks to the fetus. Limited data are available for breastfeeding, and the drug may pass into breast milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their clinician.

To request Melus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Meloxicam offers a relatively higher selectivity for COX‑2 compared with non‑selective NSAIDs such as ibuprofen, potentially providing similar analgesic efficacy with a lower incidence of gastrointestinal irritation. However, it still carries cardiovascular and renal risks similar to other NSAIDs, so individual patient risk profiles guide the choice of therapy.

Melus should be stored at temperatures below 25 °C in its original packaging. Protect the product from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Melus is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce mild gastrointestinal discomfort that some patients experience.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), hepatic injury, and renal impairment. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Meloxicam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients who have had a recent coronary artery bypass graft. It should also be used with caution in patients with impaired renal or hepatic function.